BioSpace News Archive

 Blue Mountain Quality Resources (“Blue Mountain”), a developer of enterprise asset management products and services for the Life Sciences industry, today announced that it has re

CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced a restructuring of its partnership with Juventas Cell Therapy Ltd. relating to CNCT19, an investigational CD19 CAR-T Cell therapy.

Aclipse Therapeutics was awarded a US$720,000 drug development grant from FightMND for the development of M102, a targeted therapy for Amyotrophic Lateral Sclerosis

Guide Sensmart, a world leading manufacturer of infrared thermal imaging systems, has had its IR236 IR Fever Warning System added to the list of authorized medical devices for uses related to COVID-19 by Health Canada.

Bristol Myers Squibb Canada and Acceleron Pharma Inc. announced that Health Canada has approved REBLOZYL® for the treatment of adult patients with red blood cell transfusion-dependent anemia associated with beta-thalassemia.1 REBLOZYL® is the first and only erythroid maturation agent in Canada, representing a new class of treatment for eligible patients.

Rockwell Automation, Inc., a global leader in industrial automation and digital transformation, announced it has earned the Diversity & Inclusion Program Award from The Society of Women Engineers.

Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that the first patient has been dosed in its clinical study evaluating Microbiome Metabolic Therapy (MMT™) candidate KB295 in patients with mild-to-moderate ulcerative colitis (UC).

Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first subject in its Phase 1 trial of ZT-01.

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will participate in a Virtual Fireside Chat during the Chardan Genetic Medicines Conference on October 6th at 9 a.m.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that its research team has discovered that a molecule within its portfolio of antimetabolites has displayed significant in vitro antiviral activity against SARS-CoV-2.